All News
RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.
Read Article
EULAR 2019 Report – Day 2
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. It was a full and lively second day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day two at EULAR 2019.
Read Article
Disparities in Lupus Survival
MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively).
Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.
ACP Supports Transparency of Health Care Costs
The American College of Physicians (ACP) is encouraged by the Trump administration’s executive order to improve transparency of health care costs.
Read Article
Steroids in GCA and PMR Increase Infectious Risk
A large study of UK family practice patients shows that polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) patients treated with glucocorticoids are at an increased risk of bacterial, viral, parasitic and fungal infection, even at daily doses of less than 5 mg prednisolone.
Read Article
EULAR 2019 - Podcast #1
This EULAR 2019 Podcast is a compilation of audio clips from EULAR 2019 in Madrid.
Read Article
ACP Guidelines on Developing Evidence Based Clinical Guidelines
Recommendations for the screening, diagnosis, and treatment of various diseases often differ by organization, making it difficult to know which ones to follow.
Read Article
Is Methotrexate Necessary with Tofacitinib?
Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.
Read Article
EULAR 2019- Day 4 Report
Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.
Below are the top “LB” presentations from EULAR this year:
Read Article
RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)
Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.
1. Genovese Vagal nerve stimulator in RA
Read Article
EULAR 2019 Report – Day 2
It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid
Read Article
Industry Press Releases from EULAR19
Many of the great presentations from EULAR 2019 feature industry sponsored clinical trials. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read Article
Preview of EULAR 2019 Abstracts
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
Read Article
Updated 2018 EULAR Recommendations for the Diagnosis of Gout
The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.
Read Article
More Trouble for Mallinckrodt’s Acthar Gel
Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.
Read Article
FDA Public Review of CBD Oil
The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.
Read Article
Might IL-17 Inhibition Be Effective in RA?
Interleukin 17 (IL-17) inhibitors are highly effective and FDA approved for use in psoriasis, psoriatic arthritis and ankylosing spondylitis. However, many of the initial trials were done in rheumatoid arthritis (RA) where it was projected to be effective, but was not. A recent metanalysis examines how effective IL-17 inhibition was in two RA populations: biologic-naïve or tumor necrosis factor inhibitor inadequate responders (TNF-IR).
Read Article
ACR Announces New Executive Vice President Steven Echard
The American College of Rheumatology (ACR) Board of Directors is pleased to announce that Steven C. Echard, IOM, CAE is the new Executive Vice President (EVP) of the American College of Rheumatology.
Read Article
RheumNow Podcast – Rituximab Monitoring (5.31.19)
Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com
Read Article